Skip to content

Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy

Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06653361
Enrollment
120
Registered
2024-10-22
Start date
2022-09-01
Completion date
2024-02-28
Last updated
2024-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proliferative Diabetic Retinopathy - High Risk

Keywords

Diabetic retinopathy, Laser photocoagulation, Fluorescein angiography

Brief summary

Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation. The study aims to compare ultra-widefield fluorescein angiography-based targeted retinal photocoagulation and panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.

Interventions

PROCEDUREGreen laser

Green Laser

Sponsors

Khyber Teaching Hospital
CollaboratorOTHER
Hayatabad Medical Complex
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* proliferative diabetic retinopathy (PDR) with neovascularization on the disc or elsewhere in the retina

Exclusion criteria

* Participants with a history of previous history of: * retinal photocoagulation * vitreoretinal surgery * tractional retinal detachment * epiretinal membrane * vitreomacular traction * glaucoma * uveitis * media opacities like cataract, corneal opacity, vitreous hemorrhage * anti-VEGF injections in last 3 months

Design outcomes

Primary

MeasureTime frameDescription
BCVA2 monthsBest Corrected Visual Acuity
CMT2 monthsCentral Macular Thickness
MD2 monthsMean Deviation
VFI2 monthsVisual Filed Index

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026